The combination of sacubitril and valsartan results in fewer renal events and slows kidney disease progression vs valsartan alone in patients with heart failure (HF) and preserved ejection fraction (HFrEF) in the post-hoc analysis of 5,000 patients from the PARAGON-HF trial.
The prognosis and the optimal doses of guideline-directed medical therapy (GDMT) for heart failure (HF) appear to be different between men and women, according to leading cardiologist Professor Carolyn Lam from the Duke-National University of Singapore.
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.
The use of thiazides appears to contribute to an increased risk of stroke in patients with type 2 diabetes, specifically in those receiving intensive blood pressure (BP) control, a recent study has found.
Endovascular treatment for ischaemic stroke produces improvements in functional outcome and other clinical, imaging and safety outcome measures. The treatment effect is similar between men and women, with the latter even having more years of healthy life, as shown in the results of two recent studies.
A renal resistive index (RRI) of ≥0.8 was associated with an increased risk of cardiovascular (CV) events in ASCVD* patients with preserved ejection fraction (EF) but not in those with mid-range or reduced EF, according to a study presented at ESC Asia 2019.
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
While a diagnosis of cancer is often met with concern and devastation, the same is barely true for heart failure. However, the mortality rate for those suffering from heart failure is worse than some common cancers, such as prostate and breast cancers.